Stem Cell Transplantation
Alemtuzumab may increase EBV infection risk in stem cell graft recipients
Published in Blood Weekly, September 18th, 2003
In a recent study from England, "the recovery of circulating antigen-specific T-cell immunity to Epstein-Barr virus (EBV) was determined in ELIspot assays following allogeneic myeloablative or nonmyeloablative stem cell transplantation (MST/NST)."
"In eight of 12 MST patients receiving an alemtuzumab-treated graft, the frequency of the EBV-specific reactivities was similar to or greater than that seen in the healthy controls," according to S. Chakrabarti and coauthors at the University of Birmingham. "A response was detectable in three of six...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-09-18)
More Articles from Blood Weekly
- Stem Cell Transplantation
Cord blood transplants improve long-term hematopoietic function - Transfusion Medicine
Diaspirin-crosslinked hemoglobin reduces perioperative transfusion needs - Acute Renal Failure
Natriuretic peptides that can help the kidney are increased in circulation - Blood Substitutes
PEG-Hb solution can extend cardiac preservation time - Crohn Disease
Autologous stem cell transplantation can lead to durable Crohn disease remission - Stem Cell Transplantation
Interleukin-1 degrades stem cell function after chemotherapy or radiation treatment - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
